Several investment firms have recently modified their interests in Teva Pharmaceutical Industries Limited, with shares being both acquired and sold. HSBC Holdings PLC and Vanguard Personalized Indexing are among firms who have recently added more shares, while PNC Financial Services Group, EverSource Wealth Advisors LLV, and Nomura Asset Management reduced their positions. Meanwhile, Teva's stock has witnessed high fluctuations, with five-year losses reaching 55% and a devastating US$600m in value. Despite this, the stock just experienced a surge, hitting a five-year high.
Boosted by successful trial results and Q1 earnings, it received a consensus recommendation of 'Moderate Buy.' Bank of America raised its price target for Teva to $21.00. Teva's Adderall is back in stock, with institutional investors, owning 65% of shares, considering Teva a favorite. Insider sales were reported, with Amir Weiss, Chief Accounting Officer, and Eliyahu Kalif, EVP & CFO, selling significant shares. An unusual call options activity was observed after Q1 results. However, Teva still faces difficulties with its balance sheet, causing concerns for some investors.
Teva Pharmaceutical Stocks News Analytics from Wed, 02 Aug 2023 07:00:00 GMT to Sun, 02 Jun 2024 12:23:46 GMT - Rating 1 - Innovation 2 - Information 7 - Rumor -3
